Phase 2 Expanded Access Study of UC-MSC in DMD Patients | MicrobiomeTrials← Back to trialsNCT06579352
Phase 2 Expanded Access Study of UC-MSC in DMD Patients
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-08-05Est. Completion: 2028-10-31
Enrollment target: 35 participants Locations- Other locations - TBD, Dallas, Texas, United States
- Neurology Rare Disease Center, Flower Mound, Texas, United States
Other microbiome trials you might be interested in
Duchenne Muscular Dystrophy (DMD)
This open-label extension study aims to evaluate the long-term safety and tolerability of weekly BMN 351 infusions, as w…
Milan, ItalyCompleted Dec 2031
Duchenne Muscular Dystrophy
This is a randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy, safety, and tolerabi…
Leuven, BelgiumEst. completion Feb 2028